Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Employee Benefits topic
No spam. Unsubscribe anytime.
County asks consultants to model coverage options for GLP‑1 weight‑loss drugs; commissioners cautious about adding benefit now
Summary
After a presentation by consultants on GLP‑1 medications used for diabetes and weight management, commissioners directed staff to return with modeled cost‑sharing options and implementation scenarios rather than adding coverage immediately.
Monroe County employee‑benefits staff and consultants from Gallagher briefed commissioners on GLP‑1 agonist medications — a drug class used to treat type‑2 diabetes and, more recently, indicated for chronic weight management. The consultants reviewed clinical approvals, typical annual drug costs, likely utilization scenarios and controls available through the county’s pharmacy benefit manager.
Gallagher noted the medicines are effective but expensive: branded options for the weight‑loss indication have list prices in the low tens of thousands of dollars per year per patient, and utilization could materially increase county pharmacy spend if coverage were added without limits. The consultant presented modeled scenarios that ranged from a modest take‑rate (2–5 percent of eligible members) to higher uptake; under several scenarios the county’s additional annual cost could be in the mid‑six‑figure to low‑seven‑figure range depending on cost‑sharing design.
Commission discussion centered on two themes: (1) a lack of long‑term evidence showing a net healthcare cost offset from GLP‑1‑driven weight loss, and (2) fairness and budget impacts. Several commissioners said they were not ready to add these medicines as a covered benefit for weight management for all plan members; they reiterated that the county already covers GLP‑1 drugs for FDA‑approved diabetes indications and for certain comorbid conditions. Commissioner Rashawn said he opposed adding the drugs as a general benefit now and favored continued focus on wellness programs and incentives.
The board directed staff and Gallagher to prepare a follow‑up analysis with concrete plan design options — for example, defined copays or coinsurance levels, prior‑authorization clinical criteria tied to BMI and comorbidities, and an implementation timetable aligned to the county’s budget cycle. Commissioners asked staff to return with scenarios showing how many members would be covered and the county cost under different employee/plan cost‑share splits.
No change to the county’s benefits formulary was adopted at the meeting.
